Anuradha Dua, MD
Endocrinology, Diabetes & Metabolism · Alexandria, VANPI 1528079241
Payments from drug & device makers
Across 211 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$567
- Novo Nordisk$519
- Corcept Therapeutics$472
- Lilly USA, LLC$411
- Xeris Pharmaceuticals, Inc.$386
- AbbVie$242
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,64699%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 25 | $567 |
| Novo Nordisk | 26 | $519 |
| Corcept Therapeutics | 13 | $472 |
| Lilly USA, LLC | 22 | $411 |
| Xeris Pharmaceuticals, Inc. | 16 | $386 |
| AbbVie | 15 | $242 |
| Sanofi-aventis U.S. LLC | 10 | $218 |
| Boehringer Ingelheim | 9 | $206 |
| Medtronic | 4 | $196 |
| Insulet Corporation | 8 | $180 |
| AstraZeneca(2 entities) | 8 | $171 |
| Dexcom, Inc. | 7 | $131 |
| Amneal Pharmaceuticals LLC | 5 | $101 |
| Ascendis Pharma Endocrinology Inc | 4 | $99 |
| Bayer | 4 | $86 |
| Radius Health, Inc. | 3 | $85 |
| Recordati_rare_diseases_inc. | 4 | $84 |
| Madrigal Pharmaceuticals | 3 | $76 |
| BETA Bionics, Inc. | 3 | $69 |
| Sequel Med Tech, LLC | 3 | $66 |
| Tandem Diabetes Care, Inc. | 3 | $53 |
| Johnson & Johnson | 2 | $47 |
| Abbott | 2 | $35 |
| Merck | 2 | $34 |
| Antares Pharma, Inc. | 1 | $33 |
| Shire North American Group Inc | 2 | $28 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Mannkind Corporation | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$126
- Prolia$125
- RECORLEV$106
- Korlym$103
How this compares
$4,715 in reported general payments places this provider in the 70th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $159,048 |
| JardianceEmpagliflozin | 97 | $136,832 |
| TrulicityDulaglutide | 45 | $91,255 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $53,280 |
| FarxigaDapagliflozin Propanediol | 30 | $32,045 |
| SynthroidLevothyroxine Sodium | 311 | $28,334 |
| MounjaroTirzepatide | 18 | $24,050 |
| ProliaDenosumab | 12 | $21,177 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $16,879 |
| Novolog FlexpenInsulin Aspart | 25 | $13,063 |
| VascepaIcosapent Ethyl | 12 | $12,216 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $10,193 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $7,120 |
| HumalogInsulin Lispro | 22 | $6,723 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $5,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $519 | $159,04876 claims |
| Boehringer IngelheimJardiance | $206 | $136,83297 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $411 | $122,02985 claims |
| AstraZenecaFarxiga | $171 | $32,04530 claims |
| AbbVieSynthroid | $242 | $28,334311 claims |
| AmgenProlia | $567 | $21,17712 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $101 | $3,094130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Alexandria
- Albert CooAlexandria$17K
- Aytan MammadovaAlexandria$8K
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.